Results 31 to 40 of about 255,027 (296)

The allogeneic dilemma [PDF]

Bone Marrow Transplantation, 2007
The place of allogeneic SCT in the management of multiple myeloma remains controversial. Although it may induce long-term clinical and molecular remissions, the very high transplant-related toxicity after a myeloablative preparative regimen has limited its role to younger patients as first-line treatment option. Even with this limited indication, toxic
openaire   +2 more sources

Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?

Cells
This last decade, chimeric antigen receptor (CAR) T-cell therapy has become a real treatment option for patients with B-cell malignancies, while multiple efforts are being made to extend this therapy to other malignancies and broader patient populations.
Caroline Lonez, E. Breman
semanticscholar   +1 more source

Mechanisms of Resistance to CAR T-Cells and How to Overcome Them

Methods and Protocols
In the last few decades, chimeric antigen receptor (CAR) T-cell therapy has led to a paradigm shift in the treatment of hematological malignancies, including various subtypes of B-cell non-Hodgkin’s lymphoma, B-cell acute lymphoblastic leukemia, and ...
Luca Legato, Matteo Bisio, Filippo Fasano, Corrado Benevolo Savelli, Carolina Secreto, Chiara Maria Dellacasa, Barbara Botto, Alessandro Busca, Marco Cerrano, Roberto Freilone, Mattia Novo   +10 more
doaj   +1 more source

Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle

Frontiers in Oncology, 2017
Multiple myeloma (MM) cure remains elusive despite the availability of newer anti-myeloma agents. Patients with high-risk disease often suffer from early relapse and short survival.
Ehsan Malek, Najla El-Jurdi, Nicolaus Kröger, Marcos de Lima   +3 more
doaj   +1 more source

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia

Frontiers in Oncology, 2022
Despite advances in the understanding of the genetic landscape of acute myeloid leukemia (AML) and the addition of targeted biological and epigenetic therapies to the available armamentarium, achieving long-term disease-free survival remains an unmet ...
Oren Pasvolsky, Oren Pasvolsky, Oren Pasvolsky, May Daher, Gheath Alatrash, David Marin, Naval Daver, Farhad Ravandi, Katy Rezvani, Elizabeth Shpall, Partow Kebriaei   +10 more
doaj   +1 more source

Acute Lung Injury in a Healthy Peripheral Blood Stem Cell Donor Following Granulocyte‐colony Stimulating Factor Administration: A Case Report

eJHaem
Granulocyte‐colony stimulating factor (G‐CSF) is routinely used for peripheral blood stem cells (PBSC) mobilization in healthy donors for allogeneic hematopoietic stem cell transplantation, with mild, transient adverse effects.
Nihar Desai, Tommy Alfaro Moya, Michele Heffering‐Cardwell, Felipe Tijmes Sanchez, Fotios V. Michelis, Arjun Datt Law   +5 more
doaj   +1 more source

Immune Escape of Relapsed AML Cells after Allogeneic Transplantation

New England Journal of Medicine, 2018
BACKGROUND As consolidation therapy for acute myeloid leukemia (AML), allogeneic hematopoietic stem‐cell transplantation provides a benefit in part by means of an immune‐mediated graft‐versus‐leukemia effect.
Matthew J. Christopher, A. Petti, M. Rettig, Christopher A. Miller, E. Chendamarai, E. Duncavage, J. Klco, Nicole M. Helton, M. O'Laughlin, C. Fronick, R. Fulton, R. Wilson, L. Wartman, J. Welch, S. Heath, J. Baty, J. Payton, T. Graubert, D. Link, M. Walter, P. Westervelt, T. Ley, J. Dipersio   +22 more
semanticscholar   +1 more source

Cognitive Functioning in Vorinostat‐Treated Pediatric and Young Adult Patients Over the First 180 Days After Hematopoietic Stem Cell Transplant

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Cognitive and psychological difficulties could negatively interfere with treatment adherence and quality of life before and after hematopoietic stem cell transplant (HSCT). Methods to mitigate these changes may have positive effects on treatment success.
Kristen L. Votruba, Michelle Rozwadowski, Thomas Braun, April Rahrig, Edward Peres, Kirsten M. Williams, Vanessa Fabrizio, Julie‐An Talano, Carrie L. Kitko, Nicolas Parnell, Pavan Reddy, Sung Won Choi   +11 more
wiley   +1 more source

Optimizing Access to Unrelated Donors in Canada: Re-Examining the Importance of Donor Factors on Outcomes Following Hematopoietic Cell Transplantation

Current Oncology
HLA-matched allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for many patients. Unrelated HLA-matched donors are the most frequently used donor for HCT.
Gaganvir Parmar, Matthew D. Seftel, Kathy Ganz, John Blake, Jelena L. Holovati, David S. Allan   +5 more
doaj   +1 more source

A PRSZT Registry Analysis of Prognostic Factors Influencing Survival and Relapse Rates After Second Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT A second allogeneic (allo‐)hematopoietic stem cell transplantation (HSCT2) is a potential curative option for pediatric patients with acute lymphoblastic leukemia (ALL) following relapse after first allogeneic transplantation (HSCT1), but its efficacy is limited by high relapse rates and transplant‐related toxicity in highly pretreated ...
Ava Momm, Imme Haubitz, Rita Beier, Martin Zimmermann, Andrej Lissat, Peter Bader, Matthias Eyrich, Jan‐Henning Klusmann, Matthias Wölfl, Paul‐Gerhardt Schlegel, Verena Wiegering   +10 more
wiley   +1 more source